Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Nature Medicine volume 4, pages 321–327 (1998)Cite this article

Abstract

The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Rosenberg, S.A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer. Sci. Am. 1, 89–100 (1995).

    Google Scholar 

  2. Boon, T. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy. Int. J. Cancer 54, 177–180 (1993).

    Article  CAS  PubMed  Google Scholar 

  3. Rosenberg, S.A. et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: Preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988).

  4. Rosenberg, S.A. et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst 86, 1159–1166(1994).

    Article  CAS  PubMed  Google Scholar 

  5. Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91, 6458–6462 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515–3519(1994).

    Article  CAS  Google Scholar 

  7. Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. Exp. Med. 180, 347–352 (1994).

    Article  CAS  Google Scholar 

  8. Kawakami, Y. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3461–3968 (1995).

    Google Scholar 

  9. Parkhurst, M.R. et al. Improved induction of melanoma reactive CTLs with peptides from the melanoma antigen gp100 modified at HLA-A*0210 binding residues. J. Immunol. 157, 2537–2548 (1996).

    Google Scholar 

  10. Rivoltini, L. et al. Induction of tumor-reactive CTLs from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 54, 2257–2265 (1995).

    Google Scholar 

  11. Salgaller, M.L. et al. Recognition of multiple epitopes in the human melanoma antigen gpi 00 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55, 4972–4979 (1995).

    CAS  PubMed  Google Scholar 

  12. Marincola, F.M., Rivoltini, L., Salgaller, M.L., Player, M. & Rosenberg, S.A. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence for in vivo priming by tumor cells. J. Immunother. 19, 266–277 (1996).

    Article  CAS  Google Scholar 

  13. Cormier, J.N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1 /Melan A. Cancer J. Sci. Am. USA 3, 37–44 (1996).

    Google Scholar 

  14. Salgaller, M.L., Marincola, F.M., Cormier, J.N., & Rosenberg, S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56, 4749–4757 (1996).

    CAS  PubMed  Google Scholar 

  15. Aichele, P., Hengartner, H., Zinkergnagel, R.M., & Schulz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. Exp. Med. 171, 815–1820(1990).

    Article  Google Scholar 

  16. Kast, W.M. et al. Protection against lethal sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88, 2283–2287 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Celluzzi, C.M., Mayorodomo, J.I., Storkus, W.J., Lotze, M.X., & Falo, L.D. Peptide-pulsed dendritic cells induced antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283–287 (1996).

    Article  CAS  PubMed  Google Scholar 

  18. Mandelboim, O. et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67–71 (1994).

    Article  CAS  PubMed  Google Scholar 

  19. Deres, K., Schild, H., Weismuller, K.-H., Jung, C., & Rammensee, H.-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopetide vaccine. Nature 342, 561 564 (1989).

    Article  CAS  PubMed  Google Scholar 

  20. Lasarte, J.-J., Sarobe, P., Gullon, A., Prieto, J., & Borras-Cuesta, F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-Helper synthetic peptide construct. Cell Immunol. 141, 211–218 (1992).

    Article  CAS  PubMed  Google Scholar 

  21. Shirai, M. et al. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549–556 (1994).

    CAS  PubMed  Google Scholar 

  22. Minev, B.R., Restifo, N.P., McFarland, B.J., Spiess, P.J., & Rosenberg, S.A. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54, 4155–4161 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Noguchi, Y., Richards, E.C., Chen, Y.T., & Old, L.J. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92, 2219–2223 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kyburz, D. et al. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23, 1956–1962 (1993).

    Article  CAS  PubMed  Google Scholar 

  25. Hu, X. et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56, 2479–2483 (1996).

    CAS  PubMed  Google Scholar 

  26. Jaeger, E. et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162–169 (1996).

    Article  CAS  PubMed  Google Scholar 

  27. Jaeger, E. et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67, 54–62 (1996).

    Article  CAS  Google Scholar 

  28. Marchand, M. et al. tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [Letter to the Editor]. Int. J. Cancer 63, 883–885(1995).

    Article  CAS  PubMed  Google Scholar 

  29. Rosenberg, S.A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271, 907–913(1994).

    Article  CAS  PubMed  Google Scholar 

  30. Coulie, P. et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50, 289–297 (1992).

    Article  CAS  PubMed  Google Scholar 

  31. Mazzocchi, A. et al. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer 58, 330–339 (1994).

    Article  CAS  PubMed  Google Scholar 

  32. Herr, W., Wolfel, T., Heike, M., Meyer zun Buschenfelde, K.-H., & Knuth, A. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol. Immunother. 39, 93–99 (1994).

    Article  CAS  PubMed  Google Scholar 

  33. Sharrock, C.E.M., Kaminski, E. E, & Man, S. Limiting dilution analysis of human T cells: A useful clinical tool. Immunol. Today 11, 281–286 (1990).

    Article  CAS  PubMed  Google Scholar 

  34. Gomez, I.B.A., Gomard, E., & Levy, J.P. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin. Exp. Immunol. 84, 501–507(1991).

    PubMed  PubMed Central  Google Scholar 

  35. Vasilakos, J.P., & Michael, J.G. Herpes simplex virus class l-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells. J. Immunol. 150, 2346–2355 (1993).

    CAS  PubMed  Google Scholar 

  36. Bronte, V. et al. IL-2 enhances the function of recombinant proxvirus- based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154, 4282–5292(1995).

    Google Scholar 

  37. Irvine, K.R., Roa, R.B., Rosenberg, S.A., & Restifo, N.P. Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J. Immunol. 156, 238–245 (1996).

    CAS  PubMed  Google Scholar 

  38. Rao, J.B. et al. Interleukin-12 is an effective adjuvant to recombinant vaccinia virus based tumor vaccines. J. Immunol. 156, 3357–3365 (1996).

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Steven A. Rosenberg: Correspondence should be addressed to S.A.R.

Authors and Affiliations

  1. The Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland, 20892, USA

    Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Nicholas P. Restifo, Mark E. Dudley, Susan L. Schwarz, Paul J. Spiess, Maria R. Parkhurst, Yutaka Kawakami, Claudia A. Seipp, Jan H. Einhorn & Donald E. White

Authors
  1. Steven A. Rosenberg
    View author publications

    Search author on:PubMed Google Scholar

  2. James C. Yang
    View author publications

    Search author on:PubMed Google Scholar

  3. Douglas J. Schwartzentruber
    View author publications

    Search author on:PubMed Google Scholar

  4. Patrick Hwu
    View author publications

    Search author on:PubMed Google Scholar

  5. Francesco M. Marincola
    View author publications

    Search author on:PubMed Google Scholar

  6. Suzanne L. Topalian
    View author publications

    Search author on:PubMed Google Scholar

  7. Nicholas P. Restifo
    View author publications

    Search author on:PubMed Google Scholar

  8. Mark E. Dudley
    View author publications

    Search author on:PubMed Google Scholar

  9. Susan L. Schwarz
    View author publications

    Search author on:PubMed Google Scholar

  10. Paul J. Spiess
    View author publications

    Search author on:PubMed Google Scholar

  11. Maria R. Parkhurst
    View author publications

    Search author on:PubMed Google Scholar

  12. Yutaka Kawakami
    View author publications

    Search author on:PubMed Google Scholar

  13. Claudia A. Seipp
    View author publications

    Search author on:PubMed Google Scholar

  14. Jan H. Einhorn
    View author publications

    Search author on:PubMed Google Scholar

  15. Donald E. White
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenberg, S., Yang, J., Schwartzentruber, D. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4, 321–327 (1998). https://doi.org/10.1038/nm0398-321

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/nm0398-321

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing